Compositions and methods for inhibiting the biological activity of soluble biomolecules
Inventors
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Assignees
Member
NaNoticsNaNotics is developing a new class of nanomedicine focused on the selective depletion of harmful soluble proteins implicated in cancer and other diseases. The company's injectable nanoparticle platform is designed to target and clear pathogenic soluble molecules from circulation without affecting essential membrane-bound forms, offering an innovative therapeutic approach for previously undruggable targets. The technology is modular, allowing rapid adaptation to new disease indications, and is supported by a strong patent portfolio and collaborative development with leading medical institutions.
NaNotics is developing a new class of nanomedicine focused on the selective depletion of harmful soluble proteins implicated in cancer and other diseases. The company's injectable nanoparticle platform is designed to target and clear pathogenic soluble molecules from circulation without affecting essential membrane-bound forms, offering an innovative therapeutic approach for previously undruggable targets. The technology is modular, allowing rapid adaptation to new disease indications, and is supported by a strong patent portfolio and collaborative development with leading medical institutions.
Publication Number
US-10888602-B2
Publication Date
2021-01-12
Expiration Date
Abstract
The disclosure provides, among other things, compositions that bind to and inhibit the biological activity of soluble biomolecules, as well as pharmaceutical compositions thereof. Also provided herein are a number of applications (e.g., therapeutic applications) in which the compositions are useful.
Core Innovation
The invention relates to particles having at least one surface with an agent immobilized on the surface that selectively binds a target that is a first member of a specific binding pair. Binding of the target to the immobilized agent inhibits the interaction of the target with a second member of the specific binding pair, and the target is a soluble biomolecule.
The particles further include a coating immobilized on the surface, where the coating inhibits interactions between the immobilized agent and molecules on a cell surface. This configuration is used to sequester soluble biomolecules so they become biologically inert by preventing their interaction with natural second binding partners. The disclosed concept is described in connection with anti-cancer immune dis-inhibition by scavenging soluble tumor-shed receptors, including soluble TNF receptors and soluble IL-2 receptors.
The disclosed scavenging concept is extended to other undesirable soluble factors, including toxins, viruses/virions, and pathogens. The document also describes particle design concepts aimed at reducing off-target cell-surface interactions, including porous or polydisperse particle geometries with interior immobilized agents and cell-repelling protrusions or ridges.
Optional clearance and coating strategies are described to influence distribution and clearance, including renal/hepatobiliary/phagocytic clearance concepts, masking with programmed exposure, and coatings using PEG or hydrophilic, zwitterionic, and biodegradable polymers, together with clearance-inducing approaches including CD47/PAMP-related approaches.
Claims Coverage
The document includes one independent claim. Across dependent claims, the inventive theme is implemented by specifying the identity of the immobilized agent and target, including soluble biomolecules such as soluble tumor necrosis factor receptor proteins and other proteins, and by specifying the coating as multiple moieties or molecules that inhibit agent-cell interactions.
Particle with immobilized selective-binding agent and inhibiting target interaction
A particle having at least one surface, with an agent immobilized on the surface that selectively binds a target that is a first member of a specific binding pair, wherein binding of the target to the agent immobilized on the surface inhibits the interaction of the target with a second member of the specific binding pair, and wherein the target is a soluble biomolecule.
Coating that inhibits agent interactions with cell-surface molecules
The particle further includes a coating immobilized on the surface, wherein the coating inhibits interactions between the agent immobilized on the surface and molecules on a cell surface.
Coating comprising multiple coating moieties or coating molecules
The particle includes a coating made of multiple coating moieties or coating molecules on the surface, where the multiple coating molecules inhibit interactions between the agent and cell-surface molecules.
Agent is an antibody or antibody-binding fragment
The particle has an agent immobilized on the surface that is an antibody or a biomolecule-binding fragment of an antibody.
Soluble targets include soluble tumor necrosis factor receptor protein, toxin, or viral protein
The antibody or antibody-binding fragment binds to a soluble tumor necrosis factor receptor protein, a toxin, or a viral protein.
The claims center on particles that display an immobilized selective-binding agent that scavenges a soluble biomolecule target and inhibits the target’s interaction with the second member of the specific binding pair, while a surface coating suppresses undesired interactions between the immobilized agent and cell-surface molecules; dependent claims further specify coating structure and narrow the agent and soluble target types.
Stated Advantages
Anti-cancer immune dis-inhibition by scavenging soluble tumor-shed receptors.
Targets become biologically inert by preventing interaction with natural second binding partners.
Reduced off-target cell-surface interactions via a coating that inhibits agent interactions with cell-surface molecules.
Documented Applications
Anti-cancer contexts involving scavenging soluble tumor-shed receptors, including soluble TNF receptors and soluble IL-2 receptors.
Detoxification contexts via scavenging soluble toxins.
Viral infection contexts via scavenging soluble viral structural proteins.
Anaphylactic shock contexts via antigen scavenging.
Particle manufacture and high-level evaluation contexts including PK/biodistribution and efficacy demonstrations.
Interested in licensing this patent?